olodaterol Articles
FDA advisory panel backs Boehringer's COPD drug olodaterol
30 January 2013
Forest launches COPD product Tudorza in USA
12 December 2012
Boehringer Ingelheim highlights robust respiratory R&D pipeline; announces investment
1 November 2012
COPD market to grow to more than $13.4 billion in 2020
19 December 2011
Showing 1-5 of 5 articles
- 1
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
